{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:27Z","timestamp":1761871107719,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.02.018","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T19:17:39Z","timestamp":1520018259000},"page":"e211-e218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease"],"prefix":"10.1016","volume":"18","author":[{"given":"Elodie","family":"Collinge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Loron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Virginie","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elhamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Deloire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Ducastelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorenza","family":"Barraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wattel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Paubelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.018_bib1","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.1994.tb03256.x","article-title":"Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients","volume":"86","author":"Baudard","year":"1994","journal-title":"Br J Haematol"},{"year":"2008","series-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.clml.2018.02.018_bib3"},{"key":"10.1016\/j.clml.2018.02.018_bib4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clml.2015.02.022","article-title":"Effect of age on treatment decision-making in elderly patients with acute myeloid leukemia","volume":"15","author":"Fattoum","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.02.018_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3816\/CLK.2008.n.025","article-title":"Prognostic index for older adult patients with newly diagnosed acute myeloid leukemia: The Edouard Herriot Hospital experience","volume":"2","author":"Plesa","year":"2008","journal-title":"Clin Leuk"},{"key":"10.1016\/j.clml.2018.02.018_bib9","doi-asserted-by":"crossref","first-page":"e2016009","DOI":"10.4084\/mjhid.2016.009","article-title":"Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience","volume":"8","author":"Heiblig","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2018.02.018_bib10","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.018_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia. A report on 149 patients","volume":"89","author":"Th\u00e9pot","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.018_bib12","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A\u00a0randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib13","doi-asserted-by":"crossref","unstructured":"Thomas X, Chelghoum Y. Lenalidomide in elderly acute myeloid leukemia (AML) patients with deletion 5q [del(5q)] [e-letter]. (Response to: Sekeres MA, Gundacker H, Lancet J, et\u00a0al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011; 118:523-8.) Blood (e-Letter\u2019s Web address). Published October 17, 2011, Available at: www.bloodjournal.org\/eletters.","DOI":"10.1182\/blood-2011-02-337303"},{"key":"10.1016\/j.clml.2018.02.018_bib14","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.018_bib16","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group \u2013 Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.018_bib18","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Ostgard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.018_bib19","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"Boddu","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.018_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.02.018_bib21","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib22","doi-asserted-by":"crossref","first-page":"e42334","DOI":"10.1371\/journal.pone.0042334","article-title":"Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics","volume":"7","author":"Fernandez-Mercado","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.02.018_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1200\/JCO.2005.05.202","article-title":"Treatment of secondary acute myeloid leukemia","volume":"23","author":"Pulsoni","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.018_bib24","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.24379","article-title":"Outcomes in patients who undergo aggressive induction therapy for secondary acute myeloid leukemia","volume":"115","author":"Rizzieri","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.018_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/leu.2010.279","article-title":"Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial","volume":"25","author":"Stolzel","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.018_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","article-title":"Reasons for treating secondary AML as de novo AML","volume":"85","author":"Ostgard","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.02.018_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.018_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:46Z","timestamp":1761870646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018300326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2152265018300326"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}